- Epoetin Alfa 2000iu/0.5ml (Eprex)
- Methoxy-ethylene glycol-epoietin beta 50mcg/0.3ml (Mircera®)
Advantages of Mircera
- is the first of a new class of longer-acting ESAs designed to correct and maintain Hb levels in CKD patients.
- Unlike shorter-acting ESAs, CERA’s lower affinity for erythropoietic receptors prompts repeated binding, further stimulating red blood cell production by bone marrow.
- CERA’s long half-life allows for administration once every two weeks to correct anemia and once-monthly to maintain target Hb levels
- Epoetin- alfa requires dosing once to three times per week
- Financial cost saving
- established safety and efficacy profile
Conversion from Mircera to Eprex
- Conversion from Mircera to Eprex in a cohort of patients receiving haemodialysis was not associated with a significant change in haemoglobin, achievement of haemoglobin targets, changes in intravenous iron use or indices of iron status.
- Based on nationally published costs for Mircera, Eprex and nursing time, conversion from Mircera to Eprex led to a reduction in quarterly costs of approximately £165 per patient
Table
1: Definitions of low, medium and high dose ESA
Low dose |
Medium dose |
High dose |
|
Eprex (per week)
|
<8,000iu
|
8,000
-<15,000iu
|
>15,000iu
|
Mircera (per month)
|
<100mcg
|
100
- <200mcg
|
>200mcg
|
- Anemia Drugs: Darbepoetin Alfa, Epoetin Alfa, and Methoxy Polyethylene Glycol-Epoetin Beta: Clinical Policy (Effective 02/01/2016)
- Continuous Erythropoietin Receptor Activator (Mircera®) for Renal Anemia
- Erythropoietin stimulating agent conversion from Mircera® to Eprex® at Ilkeston satellite dialysis unit: a retrospective service evaluation
- https://www.pharmac.govt.nz/medicines/my-medicine-has-changed/erythropoietin/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.